{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(1)"],"submitter":["Dean AQ"],"funding":["US Food and Drug Administration"],"pubmed_abstract":["<h4>Background</h4>Neutralising antibodies against SARS-CoV-2 are a vital component in the fight against COVID-19 pandemic, having the potential of both therapeutic and prophylactic applications. Bispecific antibodies (BsAbs) against SARS-CoV-2 are particularly promising, given their ability to bind simultaneously to two distinct sites of the receptor-binding domain (RBD) of the viral spike protein. Such antibodies are complex molecules associated with multi-faceted mechanisms of action that require appropriate bioassays to ensure product quality and manufacturing consistency.<h4>Methods</h4>We developed procedures for biolayer interferometry (BLI) and a cell-based virus neutralisation assay, the focus reduction neutralisation test (FRNT). Using both assays, we tested a panel of five BsAbs"],"journal":["Antibody therapeutics"],"pagination":["49-58"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9847335"],"repository":["biostudies-literature"],"pubmed_title":["Comparative Assessment of the Binding and Neutralisation Activity of Bispecific Antibodies Against SARS-CoV-2 Variants."],"pmcid":["PMC9847335"],"pubmed_authors":["Stauft CB","Varani L","Tan J","Dean AQ","Wang TT","Zhang B","Twomey JD"],"additional_accession":[]},"is_claimable":false,"name":"Comparative Assessment of the Binding and Neutralisation Activity of Bispecific Antibodies Against SARS-CoV-2 Variants.","description":"<h4>Background</h4>Neutralising antibodies against SARS-CoV-2 are a vital component in the fight against COVID-19 pandemic, having the potential of both therapeutic and prophylactic applications. Bispecific antibodies (BsAbs) against SARS-CoV-2 are particularly promising, given their ability to bind simultaneously to two distinct sites of the receptor-binding domain (RBD) of the viral spike protein. Such antibodies are complex molecules associated with multi-faceted mechanisms of action that require appropriate bioassays to ensure product quality and manufacturing consistency.<h4>Methods</h4>We developed procedures for biolayer interferometry (BLI) and a cell-based virus neutralisation assay, the focus reduction neutralisation test (FRNT). Using both assays, we tested a panel of five BsAbs","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2026-06-03T13:15:02.552Z","creation":"2025-04-20T13:39:19.161Z"},"accession":"S-EPMC9847335","cross_references":{"pubmed":["36683765"],"doi":["10.1093/abt/tbac032"]}}